Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ahmad Sleem & Rif S. El-Mallakh. (2021) Advances in the psychopharmacotherapy of bipolar disorder type I. Expert Opinion on Pharmacotherapy 22:10, pages 1267-1290.
Read now
Read now
Federico Mucci, Alessandra Della Vecchia, Stefano Baroni & Donatella Marazziti. (2021) Cariprazine as a therapeutic option for schizophrenia: a drug evaluation. Expert Opinion on Pharmacotherapy 22:4, pages 415-426.
Read now
Read now
Laura Orsolini, Domenico De Berardis & Umberto Volpe. (2020) Up-to-date expert opinion on the safety of recently developed antipsychotics. Expert Opinion on Drug Safety 19:8, pages 981-998.
Read now
Read now
Christoph U Correll, Rakesh Jain, Jonathan M Meyer, Antonia Periclou, Timothy Carrothers, Ágota Barabássy, Mehul Patel & Willie Earley. (2019) Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation. Neuropsychiatric Disease and Treatment 15, pages 2537-2550.
Read now
Read now
Béla Kiss, Zsolt Némethy, Károly Fazekas, Dalma Kurkó, István Gyertyán, Katalin Sághy, István Laszlovszky, Bence Farkas, Norbert Kirschner, Etelka Bolf-Terjéki, Ottilia Balázs & Balázs Lendvai. (2019) Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine. Drug Design, Development and Therapy 13, pages 3229-3248.
Read now
Read now
Gayatri Saraf, Jairo Vinícius Pinto & Lakshmi N. Yatham. (2019) Efficacy and safety of cariprazine in the treatment of bipolar disorder. Expert Opinion on Pharmacotherapy 20:17, pages 2063-2072.
Read now
Read now
Leslie Citrome. (2018) Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy. Neuropsychiatric Disease and Treatment 14, pages 2563-2577.
Read now
Read now
Articles from other publishers (58)
Ujwal Boppana, Thomas S Leonard, Ayodeji Jolayemi, Maliha I Ansari & Andrew Salib. (2023) Drug-Drug Interactions Between COVID-19 Treatments and Psychotropic Medications: An Updated Study. Cureus.
Crossref
Crossref
Reka Csehi, Viktor Molnar, Mariann Fedor, Vivien Zsumbera, Agnes Palasti, Karoly Acsai, Zoltan Grosz, Gyorgy Nemeth & Maria Judit Molnar. (2023) The improvement of motor symptoms in Huntington’s disease during cariprazine treatment. Orphanet Journal of Rare Diseases 18:1.
Crossref
Crossref
Fabian SattafMaike Scherf-Clavel, Stefan Unterecker, Andreas ReifMartina Hahn. (2023) Recommendation for a Therapeutic Reference Range of Cariprazine—A Short Communication. Therapeutic Drug Monitoring.
Crossref
Crossref
Manuela PROBO, Carla GRAMAGLIA, Cristina FERI, Paola BOSSI & Patrizia ZEPPEGNO. (2023) Improvement of psychotic symptoms in a schizophrenic subject after cariprazine add-on to clozapine. Minerva Psychiatry 64:3.
Crossref
Crossref
Rachel E. Hardy, Injae Chung, Yizhou Yu, Samantha H. Y. Loh, Nobuhiro Morone, Clement Soleilhavoup, Marco Travaglio, Riccardo Serreli, Lia Panman, Kelvin Cain, Judy Hirst, Luis M. Martins, Marion MacFarlane & Kenneth R. Pryde. (2023) The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors. Biology Direct 18:1.
Crossref
Crossref
Yarmila Elena Valencia Carlo, Ricardo Arturo Saracco-Alvarez, Verónica Angela Valencia Carlo, Daniela Vázquez Vega, Guillermina Natera Rey & Raul Ivan Escamilla Orozco. (2023) Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis. Frontiers in Psychiatry 14.
Crossref
Crossref
Collin Vas, Ayush Jain, Mili Trivedi, Manish Kumar Jha & Sanjay J. Mathew. (2023) Pharmacotherapy for Treatment-Resistant Depression. Psychiatric Clinics of North America 46:2, pages 261-275.
Crossref
Crossref
Johan Sahlsten Schölin, José Rodriguez Cruz & Stephan Hjorth. (2023) Successful switching from risperidone to cariprazine in a schizophrenic patient with pronounced functional deficit. Case report. Frontiers in Psychiatry 14.
Crossref
Crossref
Manish K. JhaSanjay J. Mathew. (2023) Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape. American Journal of Psychiatry 180:3, pages 190-199.
Crossref
Crossref
Gary S. SachsPaul P. YeungLudmyla RekedaArifulla KhanJulie L. AdamsMaurizio Fava. (2023) Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. American Journal of Psychiatry 180:3, pages 241-251.
Crossref
Crossref
Lluis Niell Galmes & Elmars Rancans. (2023) Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting. Frontiers in Psychiatry 14.
Crossref
Crossref
E. Toujani, W. Mejri, H.E. Lassoued, S. Toujani, O. Fliss, M.H.B. Cheikh & F. Safta. (2023) Development and validation of a stability-indicating high performance liquid chromatographic assay for determination of cariprazine in bulk form and in drug product. Annales Pharmaceutiques Françaises 81:1, pages 83-93.
Crossref
Crossref
Todd Riccobene, Robert RiesenbergPaul P. YeungWillie R. EarleyArlene L. Hankinson. (2022) Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia. Journal of Child and Adolescent Psychopharmacology 32:8, pages 434-443.
Crossref
Crossref
Judith Weise, Georg Schomerus & Sven Speerforck. (2022) Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome. Clinical Psychopharmacology and Neuroscience 20:2, pages 398-401.
Crossref
Crossref
Mats Bogren, Monica Soltesz & Stephan Hjorth. (2022) Remission of Persistent Negative Symptoms and Psychosocial Consequences by Combined Clozapine and Cariprazine Treatment in a Patient With Long-Standing Treatment-Resistant Schizoaffective Disorder. Frontiers in Psychiatry 13.
Crossref
Crossref
Emanuela Dyrmishi, Marco De Pieri, Marco Ferrari, Rafael Traber, Matteo Preve, Luca De Peri & Emilio Bolla. (2022) Case Report: Long-Acting Oral Cariprazine. Frontiers in Psychiatry 13.
Crossref
Crossref
Réka Csehi, Zsófia Borbála Dombi, Barbara Sebe & Mária Judit Molnár. (2022) Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies. Frontiers in Psychiatry 13.
Crossref
Crossref
Elmars Rancans, Zsófia Borbála Dombi & Ágota Barabássy. (2022) Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia. Frontiers in Psychiatry 12.
Crossref
Crossref
Ebenezer Oloyede, Ivana Clark, Shubhra Mace, Eromona Whiskey & David Taylor. (2022) Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review. Therapeutic Advances in Psychopharmacology 12, pages 204512532110666.
Crossref
Crossref
Rajdip Barman, Pradipta Majumder, Tejaswini Doifode & Anita Kablinger. (2021) Newer antipsychotics: Brexpiprazole, cariprazine, and lumateperone: A pledge or another unkept promise?. World Journal of Psychiatry 11:12, pages 1228-1238.
Crossref
Crossref
Ricardo Coentre, Rodrigo Saraiva, Carolina Sereijo & Pedro Levy. (2021) Cariprazine Use in Early Psychosis: Three Case Reports. Frontiers in Psychiatry 12.
Crossref
Crossref
André Do, Kamyar Keramatian, Ayal Schaffer & Lakshmi Yatham. (2021) Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials. Frontiers in Psychiatry 12.
Crossref
Crossref
Mehak Pahwa, Ahmad Sleem, Omar H. Elsayed, Megan Elizabeth Good & Rif S. El-Mallakh. (2021) New Antipsychotic Medications in the Last Decade. Current Psychiatry Reports 23:12.
Crossref
Crossref
Stephan Hjorth. (2021) The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective. Frontiers in Psychiatry 12.
Crossref
Crossref
Borjanka Batinic, Ivan Ristic, Milica Zugic & David S. Baldwin. (2021) Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine. Frontiers in Psychiatry 12.
Crossref
Crossref
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clinical Use of Antipsychotic Plasma Levels. The Clinical Use of Antipsychotic Plasma Levels
337
371
.
Jonathan M. Meyer & Stephen M. Stahl. 2021. The Clinical Use of Antipsychotic Plasma Levels. The Clinical Use of Antipsychotic Plasma Levels
13
33
.
Jose Rodriguez Cruz, Johan Sahlsten Schölin & Stephan Hjorth. (2021) Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction. Frontiers in Psychiatry 12.
Crossref
Crossref
István Laszlovszky, Ágota Barabássy & György Németh. (2021) Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety. Advances in Therapy 38:7, pages 3652-3673.
Crossref
Crossref
Leslie Citrome, Lakshmi N. Yatham, Mehul D. Patel, Ágota Barabássy, Arlene Hankinson & Willie R. Earley. (2021) Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression. Journal of Affective Disorders 288, pages 191-198.
Crossref
Crossref
Domenico De Berardis, Gabriella Rapini, Luigi Olivieri, Agostina Giardini, Ida De Lauretis, Nicola Serroni, Laura Orsolini, Michele Fornaro, Felice Iasevoli, Sabatino Trotta, Paolo Cottura, Federica Vellante, Marco Alessandrini & Massimo Di Giannantonio. (2021) Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. Clinical Psychopharmacology and Neuroscience 19:1, pages 174-178.
Crossref
Crossref
ShivaShanker Reddy Mukku, RaviKumar Nadella & SumanthEdiga Kornapalli. (2021) Cariprazine for late-life psychiatric illness: A review on therapeutic potential and challenges. Journal of Geriatric Mental Health 8:2, pages 77.
Crossref
Crossref
Antonia Periclou, Luann Phillips, Parviz Ghahramani, Margit Kapás, Timothy Carrothers & Tatiana Khariton. (2020) Population Pharmacokinetics of Cariprazine and its Major Metabolites. European Journal of Drug Metabolism and Pharmacokinetics 46:1, pages 53-69.
Crossref
Crossref
Andrea Fagiolini, José Ángel Alcalá, Thomas Aubel, Wojciech Bienkiewicz, Mats Magnus Knut Bogren, Joaquim Gago, Giancarlo Cerveri, Michael Colla, Francisco Collazos Sanchez, Alessandro Cuomo, Frieling Helge, Eduardo Iacoponi, Per-Axel Karlsson, Pradeep Peddu, Mauro Pettorruso, Henrique Jorge Ramos Pereira, Johan Sahlsten Schölin & Ingo Bernd Vernaleken. (2020) Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an International Panel. Annals of General Psychiatry 19:1.
Crossref
Crossref
Christoph U Correll, Koen Demyttenaere, Andrea Fagiolini, Göran Hajak, Stefano Pallanti, Giorgio Racagni & Swaran Singh. (2020) Cariprazine in the management of negative symptoms of schizophrenia: state of the art and future perspectives. Future Neurology 15:4.
Crossref
Crossref
Suresh Durgam, Willie Earley, Rui Li, Dayong Li, Kaifeng Lu, István Laszlovszky, Wolfgang Fleischhacker W.Henry A. Nasrallah. (2020) Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Ukrains'kyi Visnyk Psykhonevrolohii:Volume 28, issue 3 (104), pages 27-37.
Crossref
Crossref
Francesca Calabrese, Frank I. Tarazi, Giorgio Racagni & Marco A. Riva. (2019)
The role of dopamine D
3
receptors in the mechanism of action of cariprazine
. CNS Spectrums 25:3, pages 343-351.
Crossref
Crossref
Nicholas Keks, Judith Hope, Darren Schwartz, Harold McLennan, David Copolov & Graham Meadows. (2020) Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia. CNS Drugs 34:5, pages 473-507.
Crossref
Crossref
Antonia Periclou, Susan Willavize, David Jaworowicz, Julie Passarell, Timothy Carrothers, Parviz Ghahramani, Suresh Durgam, Willie Earley, Margit Kapás & Tatiana Khariton. (2019) Relationship Between Plasma Concentrations and Clinical Effects of Cariprazine in Patients With Schizophrenia or Bipolar Mania. Clinical and Translational Science 13:2, pages 362-371.
Crossref
Crossref
Oliver FreudenreichOliver Freudenreich. 2020. Psychotic Disorders. Psychotic Disorders
249
261
.
Oliver FreudenreichOliver Freudenreich. 2020. Psychotic Disorders. Psychotic Disorders
171
184
.
Marlene Jacobson, Wayne Childers & Magid Abou‐Gharbia. 2019. Successful Drug Discovery. Successful Drug Discovery
83
130
.
Jean-Michel Azorin & Nicolas Simon. (2019) Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder. Drugs 79:15, pages 1657-1677.
Crossref
Crossref
Massimo Carlo Mauri. (2019) Reply to Periclou et al.: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”. Clinical Pharmacokinetics 58:9, pages 1217-1218.
Crossref
Crossref
Antonia Periclou, Todd Riccobene, Margit Kapás & István Laszlovszky. (2019) Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”. Clinical Pharmacokinetics 58:9, pages 1215-1216.
Crossref
Crossref
Jillian S. Weissenrieder, Jeffrey D. Neighbors, Richard B. Mailman & Raymond J. Hohl. (2019)
Cancer and the Dopamine D
2
Receptor: A Pharmacological Perspective
. Journal of Pharmacology and Experimental Therapeutics 370:1, pages 111-126.
Crossref
Crossref
László-István Bába, Melinda Kolcsár, Imre Zoltán Kun, Zsófia Ulakcsai, Fruzsina Bagaméry, Éva Szökő, Tamás Tábi & Zsolt Gáll. (2019) Effects of Cariprazine, Aripiprazole, and Olanzapine on Mouse Fibroblast Culture: Changes in Adiponectin Contents in Supernatants, Triglyceride Accumulation, and Peroxisome Proliferator-Activated Receptor-γ Expression. Medicina 55:5, pages 160.
Crossref
Crossref
Ayman Antoun Reyad & Raafat Mishriky. (2019) Cariprazine: Pharmacology and Use in the Clinical Management of Psychiatric Disorders. Psychiatric Annals 49:3, pages 129-134.
Crossref
Crossref
Anna Herman, Mostafa El Mansari, Nika Adham, Béla Kiss, Bence Farkas & Pierre Blier. (2018)
Involvement of 5-HT
1A
and 5-HT
2A
Receptors but Not
α
2
-Adrenoceptors in the Acute Electrophysiological Effects of Cariprazine in the Rat Brain In Vivo
. Molecular Pharmacology 94:6, pages 1363-1370.
Crossref
Crossref
Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli & Alfredo Carlo Altamura. (2018) Clinical Pharmacokinetics of Atypical Antipsychotics: An Update. Clinical Pharmacokinetics 57:12, pages 1493-1528.
Crossref
Crossref
Hans-Peter Volz. (2018) D2-Rezeptor-Agonist mit Schwerpunkt Negativsymptomatik. DNP - Der Neurologe & Psychiater 19:3, pages 32-39.
Crossref
Crossref
Henry A. Nasrallah, Willie Earley, Andrew J. Cutler, Yao Wang, Kaifeng Lu, István Laszlovszky, György Németh & Suresh Durgam. (2017) The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry 17:1.
Crossref
Crossref
Bertalan Németh, Anett Molnár, Ron Akehurst, Margit Horváth, Kristóf Kóczián, György Németh, Árpád Götze & Zoltán Vokó. (2017) Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. Journal of Comparative Effectiveness Research 6:8, pages 639-648.
Crossref
Crossref
Willie Earley, Suresh Durgam, Kaifeng Lu, Marc Debelle, István Laszlovszky, Eduard Vieta & Lakshmi N. Yatham. (2017) Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies. Journal of Affective Disorders 215, pages 205-212.
Crossref
Crossref
Karly P. Garnock-Jones. (2017) Cariprazine: A Review in Schizophrenia. CNS Drugs 31:6, pages 513-525.
Crossref
Crossref
Benedicto Crespo-Facorro, Jose Maria Pelayo-Teran & Jacqueline Mayoral-van Son. (2016) Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review. Neurology and Therapy 5:2, pages 105-130.
Crossref
Crossref
Suresh Durgam, Willie Earley, Rui Li, Dayong Li, Kaifeng Lu, István Laszlovszky, W. Wolfgang Fleischhacker & Henry A. Nasrallah. (2016) Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial. Schizophrenia Research 176:2-3, pages 264-271.
Crossref
Crossref
Ragy R. Girgis, Mark Slifstein, Deepak D’Souza, Yih Lee, Antonia Periclou, Parviz Ghahramani, István Laszlovszky, Suresh Durgam, Nika Adham, Nabeel Nabulsi, Yiyun Huang, Richard E. Carson, Béla Kiss, Margit Kapás, Anissa Abi-Dargham & Ashok Rakhit. (2016) Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology 233:19-20, pages 3503-3512.
Crossref
Crossref